
The current landscape of biotechnology is undergoing a radical shift as traditional laboratory methods begin to merge seamlessly with high-performance computing to solve the world’s most complex biological puzzles. Cheiron, a pioneer in the burgeoning field of AI-native drug discovery, recently announced a successful seed funding round of $8 million led by several prominent venture capital firms looking to disrupt










